BBLG vs. SIENQ, NAOV, ACORQ, EVFM, SBFM, SINT, NMTR, SPRC, HSTO, and SCNI
Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include Sientra (SIENQ), NanoVibronix (NAOV), Acorda Therapeutics (ACORQ), Evofem Biosciences (EVFM), Sunshine Biopharma (SBFM), Sintx Technologies (SINT), 9 Meters Biopharma (NMTR), SciSparc (SPRC), Histogen (HSTO), and Scinai Immunotherapeutics (SCNI). These companies are all part of the "medical" sector.
Sientra (NASDAQ:SIENQ) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
Bone Biologics has a net margin of 0.00% compared to Bone Biologics' net margin of -65.93%. Bone Biologics' return on equity of 0.00% beat Sientra's return on equity.
In the previous week, Bone Biologics had 4 more articles in the media than Sientra. MarketBeat recorded 5 mentions for Bone Biologics and 1 mentions for Sientra. Sientra's average media sentiment score of 0.46 beat Bone Biologics' score of 0.00 indicating that Bone Biologics is being referred to more favorably in the news media.
Bone Biologics has lower revenue, but higher earnings than Sientra. Bone Biologics is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.
17.1% of Sientra shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 1.5% of Sientra shares are owned by insiders. Comparatively, 13.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Sientra has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.
Sientra and Bone Biologics both received 0 outperform votes by MarketBeat users.
Summary
Sientra and Bone Biologics tied by winning 6 of the 12 factors compared between the two stocks.
Get Bone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bone Biologics Competitors List
Related Companies and Tools
